Neurokinin 1 antagonist - Nippon-Roche

Drug Profile

Neurokinin 1 antagonist - Nippon-Roche

Alternative Names: NK-1 antagonist - Nippon-Roche

Latest Information Update: 31 Jul 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chugai Pharmaceutical
  • Class
  • Mechanism of Action Neurokinin 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Major depressive disorder

Most Recent Events

  • 31 Jul 2006 No development reported - Phase-I for Depression in Japan (unspecified route)
  • 30 Oct 2002 Nippon Roche has been merged into Chugai Pharmaceutical
  • 12 Jun 2002 Phase-I clinical trials in Depression in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top